The fourth case, an R/R AML patient with initial IDH2-R140Q mutation achieved a durable remission with enasidenib, but disease progression occured with emergence of a new IDH1-R132C mutation which was sensitive to combined blockade IDH1/2 by vorasidenib. The gene discussed is IDH2; the disease is acute myeloid leukemia.